UNDERSTANDING THE UTILITY VALUE OF PATIENTS WITH HEAVILY PRE-TREATED MULTIPLE MYELOMA

被引：0
|
作者：
Hadi, M. [1 ]
Swinburn, P. [1 ]
de Freitas, H. M. [1 ]
Ito, T. [2 ]
机构：
[1] Mapi Grp, London, England
[2] Janssen Hlth Econ & Market Access EMEA, High Wycombe, Bucks, England
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.242
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PRM175
引用
收藏
页码：A389 / A389
页数：1
相关论文
共 50 条
  • [1] Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma
    Stoehr, Elisabeth
    Schmeel, Frederic Carsten
    Schmeel, Leonard Christopher
    Haenel, Mathias
    Schmidt-Wolf, Ingo G. H.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2015, 141 (12) : 2205 - 2212
  • [2] Bendamustine in heavily pre-treated patients with relapsed or refractory multiple myeloma
    Elisabeth Stöhr
    Frederic Carsten Schmeel
    Leonard Christopher Schmeel
    Mathias Hänel
    Ingo G. H. Schmidt-Wolf
    Journal of Cancer Research and Clinical Oncology, 2015, 141 : 2205 - 2212
  • [3] Pomalidomide-Dexamethasone in the Management of Heavily Pre-Treated Multiple Myeloma
    Cerchione, Claudio
    Catalano, Lucio
    Nappi, Davide
    Pareto, Anna Emanuele
    Musaraca, Gerardo
    Lucchesi, Alessandro
    Pane, Fabrizio
    Martinelli, Giovanni
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S311 - S311
  • [4] Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
    Kim, Seok Jin
    Bang, Soo-Mee
    Choi, Yoon Seok
    Jo, Deog-Yeon
    Kim, Jin Seok
    Lee, Hyewon
    Eom, Hyeon Seok
    Yoon, Dok Hyun
    Suh, Cheolwon
    Lee, Je-Jung
    Hong, Junshik
    Lee, Jae Hoon
    Koh, Youngil
    Kim, Kihyun
    Yoon, Sung-Soo
    Min, Chang-Ki
    BLOOD RESEARCH, 2016, 51 (03) : 193 - 199
  • [5] A Real-World Study of Bendamustine Therapy in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients
    Bird, Sarah
    Panopoulou, Akaterina
    Kaiser, Martin
    Boyd, Kevin
    Pawlyn, Charlotte
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S424 - S424
  • [6] COST-EFFECTIVENESS ANALYSIS OF DARATUMUMAB IN HEAVILY PRE-TREATED MULTIPLE MYELOMA PATIENTS FOR THE ITALIAN HEALTHCARE SYSTEM
    Lo Muto, R.
    Lenzi, M.
    Franzini, J. M.
    Baggi, A.
    Bonetti, G.
    Hegenbarth, A.
    VALUE IN HEALTH, 2017, 20 (09) : A442 - A443
  • [7] Value of Functional Liver Imaging in Heavily Pre-Treated Hepatocellular Carcinoma Patients
    Schaub, S. K.
    Bowen, S. R.
    Price, R. G.
    Nyflot, M.
    Chapman, T. R.
    Apisarnthanarax, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (03): : E60 - E61
  • [8] Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma
    Papanikolaou, Xenofon
    Szymonifka, Jackie
    Rosenthal, Adam
    Heuck, Christoph J.
    Mitchell, Alan
    Johann, Donald, Jr.
    Keller, Jason
    Waheed, Sarah
    Usmani, Saad Z.
    Van Rhee, Frits
    Bailey, Clyde
    Petty, Nathan
    Hoering, Antje
    Crowley, John
    Barlogie, Bart
    HAEMATOLOGICA, 2013, 98 (07) : 1147 - 1153
  • [9] Contemporary Use of VTD-PACE As Bridge Therapy in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma
    Kurish, Heena P.
    Row, Kerri
    Kurkowski, Austin
    Rice, Mikhaila
    Rudoni, Joslyn
    Khouri, Jack
    Mazzoni, Sandra
    Samaras, Christy J.
    Williams, Louis S.
    van Heeckeren, Willem
    Valent, Jason
    Anwer, Faiz
    BLOOD, 2022, 140 : 12496 - 12497
  • [10] Bortezomib added to high-dose melphalan as pre-transplant conditioning is safe in patients with heavily pre-treated multiple myeloma
    P A Thompson
    H M Prince
    J F Seymour
    D Ritchie
    K Stokes
    K Burbury
    M Wolf
    S Peinert
    T Joyce
    S J Harrison
    Bone Marrow Transplantation, 2011, 46 : 764 - 765
12345